Novartis Ag

Sunesis Pharmaceuticals, Inc.

Ahmad Hashash

Sean Ritchie

Anantha R Sudhakar

Augustus O Okhamafe

Kangwen L Lin

Hengqin Cheng

Jeff Jacobs

Rampurna Gullapalli

Piotr Henryk Karpinski

Paul Allen Sutton

Eric M Loeser

Eduardo Sy

Peng Shen

Methods of preparing substantially pure SNS-595 substance are disclosed. Also provided are compositions comprising SNS-595 substance that are substantially pure and essentially free of visible particles.

Stable SNS-595 compositions and methods of preparation

Salts of benzimidazolyl pyridyl ethers are provided, particularly salts of {1-methyl-5-[2-(5-trifluoromethyl-1H-imidazol-2-yl)-pyridin-4-yloxy]-1H-benzoimidazol-2-yl}-(4-trifluoromethyl-phenyl)amine. Compositions and formulations including such salts and surfactants as well as methods of preparing such compositions and formulations are provided.

Salts of benzimidazolyl pyridyl ethers and formulations thereof

Formulations are provided, comprising: a compound of Formula I, a pharmaceutically acceptable salt thereof, or a mixture of any two or more thereof; and an ingredient selected from a hydrophilic solvent, a lipophilic solvent, an emulsifier, or a mixture of any two or more thereof; wherein the compound of Formula I is: In some embodiments, the formulations are liquids. In other embodiments, the formulations are solids. Also provided are methods of preparing such formulations.

Formulations for benzimidazolyl pyridyl ethers

The present invention is directed to solid forms of the Raf kinase inhibitor 1-methyl-5-(2-(5-(trifluoromethyl)-1H-imidazol-2-yl)pyridin-4-yloxy)-N-(4-(trifluoromethyl)phenyl)-1H-benzo[d]imidazol-2-amine, as well as compositions thereof and uses of the same.

Solid forms of a Raf kinase inhibitor

Growing community of inventors

Pleasant Hill, CA, United States of America

Ahmad Hashash